172 related articles for article (PubMed ID: 27786232)
1. Europe's drug regulator opens vaults of clinical-trials data.
Abbott A
Nature; 2016 Oct; 538(7626):440. PubMed ID: 27786232
[No Abstract] [Full Text] [Related]
2. Drug company drops case after EMA agrees to redactions in some documents to be published.
Dyer C
BMJ; 2014 Apr; 348():g2632. PubMed ID: 24709373
[No Abstract] [Full Text] [Related]
3. European regulator is urged to release data on drugs approved in past 10 years.
Kmietowicz Z
BMJ; 2013 Sep; 347():f5905. PubMed ID: 24081901
[No Abstract] [Full Text] [Related]
4. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
5. Drug companies should release data from all trials of licensed drugs, say MPs.
Hawkes N
BMJ; 2013 Jan; 346():f321. PubMed ID: 23325880
[No Abstract] [Full Text] [Related]
6. EMA opens its data vaults.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(12):811. PubMed ID: 27895332
[No Abstract] [Full Text] [Related]
7. Predictable materiality: a need for common criteria governing the disclosure of clinical trial results by publicly-traded pharmaceutical companies.
Cohen K; Cormier JW; Davar MV
J Contemp Health Law Policy; 2013; 29(2):201-32. PubMed ID: 23837261
[No Abstract] [Full Text] [Related]
8. Drug-company data vaults to be opened.
Cressey D
Nature; 2013 Mar; 495(7442):419-20. PubMed ID: 23538802
[No Abstract] [Full Text] [Related]
9. AbbVie considers harms to be commercially confidential information: sign a petition.
Gøtzsche PC
BMJ; 2013 Dec; 347():f7569. PubMed ID: 24366821
[No Abstract] [Full Text] [Related]
10. European drug agency under fire: critics charge that trial data are too inaccessible.
Hampton T
JAMA; 2011 Aug; 306(6):593-5. PubMed ID: 21828315
[No Abstract] [Full Text] [Related]
11. Transparency in drug regulation: mirage or oasis?
Lexchin J; Mintzes B
CMAJ; 2004 Nov; 171(11):1363-5. PubMed ID: 15557590
[No Abstract] [Full Text] [Related]
12. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
13. Researchers see a need for speed in EU trial approvals.
Cressey D
Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
[No Abstract] [Full Text] [Related]
14. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
Gitter DM
Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
[No Abstract] [Full Text] [Related]
15. Europe. Drug watchdog ponders how to open clinical trial data vault.
Rabesandratana T
Science; 2013 Mar; 339(6126):1369-70. PubMed ID: 23520086
[No Abstract] [Full Text] [Related]
16. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
17. Rent increase hits Europe's drug regulator before Brexit move.
Vesper I
Nature; 2018 Apr; 556(7702):418. PubMed ID: 29691518
[No Abstract] [Full Text] [Related]
18. Adjustment of Europe's drug regulation to public- health needs.
Wolff F
Lancet; 2001 Nov; 358(9294):1733-4. PubMed ID: 11728586
[No Abstract] [Full Text] [Related]
19. Maine law requires drug companies to provide clinical trial data.
Appell D
J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
[No Abstract] [Full Text] [Related]
20. A taxpayer-funded clinical trials registry and results database.
Turner EH
PLoS Med; 2004 Dec; 1(3):e60. PubMed ID: 15562322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
